Abstract
This study aims to determine whether socioeconomic status (SES) is associated with participation in melanoma clinical trials. A retrospective, single-center observational study was conducted at the Melanoma Institute Australia. Factors affecting clinical trial participation were assessed using logistic regression. Of 9074 patients, 2304 (25%) participated in a clinical trial. Multivariate analysis indicated males compared with females (odds ratio [OR]: 1.18; 95% CI: 1.07-1.30) and patients with American Joint Cancer Committee stage II or III disease (but not stage IV disease) were more likely to participate in trials than patients with stage I disease (OR: 2.81 [95% CI: 2.50-3.16] and OR: 4.55 [95% CI: 3.91-5.30], respectively). SES did not affect trial participation. Our data suggest that SES is not a significant predictor of melanoma clinical trial participation when adjusted for other factors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
